What analysts say:
- Buy, sell, or hold?: Analysts strongly back Stryker, with 21 of 27 rating it a buy and the remainder rating it a hold. Analysts like Stryker better than competitor Zimmer Holdings overall. Wall Street has warmed to the stock over the past three months, with analysts increasing their endorsement from Hold to Moderate buy.
- Revenue Forecasts: On average, analysts predict $2.04 billion in revenue this quarter. That would represent a rise of 15.3% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of 89 cents per share. Estimates range from 86 cents to 92 cents.
What our community says:
CAPS All Stars are solidly behind the stock with 98.3% assigning it an "outperform" rating. The community at large concurs with the All Stars with 97.9% granting it a rating of "outperform." Fools are keen on Stryker and haven't been shy with their opinions lately, logging 368 posts in the past 30 days. Stryker has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
Stryker's profit has risen year over year by an average of 9.1% over the past five quarters. Revenue has now gone up for three straight quarters. The company's gross margin shrank by 4.2 percentage points in the last quarter. Revenue rose 16.3% while cost of sales rose 32.2% to $712.8 million from a year earlier.
For all our Stryker-specific analysis, including earnings and beyond, add Stryker to My Watchlist.
Motley Fool newsletter services have recommended buying shares of Stryker.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.